Development of TP-317 for Ulcerative Colitis
Funded at Thetis Pharmaceuticals, LLC · NIH-11406737 · Data updated 2026-11-12
A new therapy approach for ulcerative colitis aims to repair the intestinal lining and restore immune balance in people with UC, addressing a need for patients who don’t fully respond to current treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thetis Pharmaceuticals, LLC NIH-funded |
| Lab location | 1 site (Deep River, United States) |
| Project start | September 22, 2026 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $669,925 |
| NIH project number | 1SB1DK145287-01A1 |
| Project ID | NIH-11406737 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with ulcerative colitis or inflammatory bowel disease who have limited response to standard therapies and are candidates for novel epithelial-repair–focused treatments.
✕Less likely to help
Patients whose disease biology does not primarily involve epithelial repair pathways or who are not eligible for early-phase research may not benefit.
What this research studies
This project focuses on ulcerative colitis and Crohn's disease, aiming to improve long-term remission by targeting epithelial repair and immune homeostasis. It investigates Resolvin E1 as a partial BLT1 agonist to promote healing while reducing inflammation. The work centers on overcoming the chemical instability of RvE1 by developing a more stable compound, TP-317, for patients with inflammatory bowel disease. If successful, the therapy could offer an alternative to broad immunosuppression with potentially fewer side effects.
Why it matters
Potential benefit: If successful, patients with ulcerative colitis could experience better mucosal healing and longer-lasting remission with fewer adverse effects compared to some current therapies.
How similar studies have gone: Prior approaches targeting epithelial repair and BLT1 signaling have shown promise in preclinical models, but this specific TP-317 strategy is a novel development.
Where this research is happening
-
Thetis Pharmaceuticals, LLC
Deep River, United States Active
Researchers
- Principal investigator: Parkinson, John — Thetis Pharmaceuticals, LLC
- Study coordinator: Parkinson, John
Related research
Other NIH-funded projects on the same topics.
-
Outpatient pathway for severe ulcerative colitis in the right care setting
This study tests a safe, outpatient approach using an oral therapy and remote monitoring for people with acute severe ulcerative colitis to avoid hospitalization.
-
Fh15-based therapy to calm inflammation in sepsis and ulcerative colitis
A research project tests a molecule from a parasitic organism (Fh15) to reduce harmful inflammation in adults with sepsis or ulcerative colitis.
-
IMYX-3 treatment for ulcerative colitis
A new therapy approach called IMYX-3 aims to help adults with moderate to severe ulcerative colitis who have not responded well to current treatments.
-
Autoantibodies and ulcerative colitis: how avb6 antibodies may drive disease
This NIH grant aims to understand how antibodies against a gut cell protein (αvβ6) may actively contribute to ulcerative colitis and what that means for future treatments.
-
Selenium supplementation to help moderate-severe ulcerative colitis flare-ups
This grant tests whether giving selenium can help people with moderate to severe ulcerative colitis reduce flares and improve symptoms.
-
Sulfite and mitochondrial function in pediatric ulcerative colitis
A child-focused project will study how sulfites in the diet affect mitochondria and gut lining cells in kids with ulcerative colitis.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.